International audienceThe identification of ALK and ROS1 rearrangements has become essential for the theranostic management of patients with non-small cell lung cancer, especially in stage IV or inoperable patients. These testings are now performed by immunohistochemistry on histological samples and confirmed by fluorescent in situ hybridization in case of positive or doubtful results. The diagnosis of lung cancer is often performed at an advanced or metastatic stage and cytological sample could be the only material containing malignant cells available at these stages. Therefore, the detection of ALK and ROS1 rearrangement by immunocytochemical analysis on cytological specimens is needed. We performed this test on 27 cytological samples of ...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
International audienceThe identification of ALK and ROS1 rearrangements has become essential for the...
International audienceThe detection of molecular alterations such as ROS1 and ALK rearrangements is ...
International audienceThe detection of ROS1 and ALK rearrangements is performed for advanced-stage n...
Background The identification of ALK and ROS1 rearrangements and the availability of an effective ta...
Cytologic sampling is the mainstay of diagnosing advanced lung cancer. Moreover, to select patients ...
The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cance...
Data de publicació electrònica: 19-04-2021The effectiveness of targeted therapies with tyrosine kina...
Aims Several predictive biomarkers of response to specific inhibitors have become mandatory for the ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
IntroductionAccurate determination of ALK rearrangement is important in lung cancer patients, especi...
INTRODUCTION: Lung cancer is often diagnosed by cytology, necessitating predictive molecular marker ...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
International audienceThe identification of ALK and ROS1 rearrangements has become essential for the...
International audienceThe detection of molecular alterations such as ROS1 and ALK rearrangements is ...
International audienceThe detection of ROS1 and ALK rearrangements is performed for advanced-stage n...
Background The identification of ALK and ROS1 rearrangements and the availability of an effective ta...
Cytologic sampling is the mainstay of diagnosing advanced lung cancer. Moreover, to select patients ...
The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cance...
Data de publicació electrònica: 19-04-2021The effectiveness of targeted therapies with tyrosine kina...
Aims Several predictive biomarkers of response to specific inhibitors have become mandatory for the ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
IntroductionAccurate determination of ALK rearrangement is important in lung cancer patients, especi...
INTRODUCTION: Lung cancer is often diagnosed by cytology, necessitating predictive molecular marker ...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...